Overview

Study Evaluating Antibiotic Utilization Measures and Control of Extended-Spectrum-Lactamases (ESBLs)

Status:
Completed
Trial end date:
2005-03-01
Target enrollment:
0
Participant gender:
All
Summary
- To determine the value of using piperacillin/tazobactam in reducing the cases of ESBL producing E. coli or K. pneumoniae colonization and infection. - To determine the acquisition rate of ESBL producing E. coli or K. pneumoniae, both pre and post intervention in the selected medical centers.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Anti-Bacterial Agents
Criteria
Inclusion Criteria:

- Patients admitted or transferred to the ICU/pulmonary/hematology units.

- Patients of either sex, 18 years of age or older

Exclusion Criteria:

- Pregnant and nursing women. Female of childbearing potential without using any birth
control methods. Female of childbearing potential using oral contraceptives during
study period. (Note: penicillin and beta-lactamase inhibitors may prevent oral
contraceptives from working properly, increasing the chance of pregnancy).

- Patients who have the contraindications of using Tazocin (pipercillin/tazobactam)

Other exclusions apply.